GB Sciences, Inc. (GBLX)
| Market Cap | 122.12K |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -1.14M |
| Shares Out | 407.07M |
| EPS (ttm) | -0.00 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,000 |
| Average Volume | 32,229 |
| Open | 0.0002 |
| Previous Close | 0.0003 |
| Day's Range | 0.0002 - 0.0002 |
| 52-Week Range | n/a |
| Beta | 9.83 |
| RSI | 45.18 |
| Earnings Date | Jul 7, 2025 |
About GB Sciences
GB Sciences, Inc., a plant-based research and biopharmaceutical drug development company. The company offers cannabis inspired medicines and complex therapeutic mixtures for the prescription drug market. Its intellectual property covers a range of medical conditions and programs in pre-clinical animal stage for Parkinson’s disease, neuropathic pain, chronic pain, cytokine release syndrome, stress/anxiety/depression, and cardiovascular therapeutic programs. The company was formerly known as Growblox Sciences, Inc. and changed its name to GB Scie... [Read more]
Financial Performance
Financial StatementsNews
Gb Sciences Identifies Novel Cannabis-Inspired Mixtures as Anti-Inflammatory Therapies Based on Proprietary AI-Enabled Drug Discovery Platform
Gb Sciences' innovative approach harnesses the power of plant-based treatments as simplified mixtures that target dangerous hyperinflammatory responses to viral infections. Gb Sciences' innovative app...
Gb Sciences Addresses Growing Need for Anxiety and Depression Medications With Non-Psychedelic, Kava-Based Formulations
As mental health disorders increasingly impact global populations, Gb Sciences is developing psychotropic but non-psychedelic treatments for anxiety and depression that compete with the emerging billi...
Gb Sciences Co-Publishes Study Demonstrating Anti-Inflammatory Properties of Cannabis Ingredients
As published in the journal Food and Chemical Toxicology, the biopharmaceutical drug development firm's sponsored research used co-cultured human, primary immune cells as a model to evaluate the abili...
TODAY: Gb Sciences' President Demonstrates Benefits of AI-Enabled Drug Discovery Engine for Novel Plant-Inspired Pharmaceuticals at 10th Annual Drug Discovery Strategic Summit
At the Annual Summit, Dr. Andrea Small-Howard is presenting a Keynote Address that includes data from case studies demonstrating the utility of Gb Sciences' proprietary PhAROS drug discovery platform....
Gb Sciences' Plant-based Formulations Designed to Treat Anxiety Achieve Statistical Significance in Animal Study
Gb Sciences' anxiety formulations were previously identified using the company's AI-driven PhAROS™ platform, and they have now been evaluated using preclinical zebrafish models of stress at the Nation...
TODAY: Gb Sciences' President Demonstrates Effectiveness of Simplified Therapeutic Mixtures Inspired by Cannabis Plant Extracts at Canna Pharma 2022 Conference
Dr. Andrea Small-Howard discusses the company's novel process for developing disease-specific, cannabinoid-based therapeutics. Dr. Andrea Small-Howard discusses the company's novel process for develop...
Gb Sciences Co-Publishes Study Demonstrating Efficacy of Its Proprietary Cannabinoid Mixtures for the Treatment of Parkinson's Disease
As published in Frontiers in Pharmacology, the biopharmaceutical drug development firm's sponsored research has identified and validated cannabinoid ratio-controlled, Minimum Essential Mixtures (MEM) ...
TODAY: Gb Sciences Describes Drug Development Progress in Pharma's Almanac Journal Article
Gb Sciences is focusing considerable resources on bringing its lead Parkinson's disease formulations to the clinic with promising results; plus, new data validating the efficacy of their novel anxiety...
Gb Sciences is Leading Digital Transformation in Biopharma Industry Through Its Novel AI-Accelerated Drug Discovery Platform—PhAROS™
As digitization becomes a necessity in the life sciences industry, Gb Sciences proves it's already ahead of the curve with its own revolutionary technology. As digitization becomes a necessity in the ...
Gb Sciences Leads Digital Transformation in Biopharma Industry Through Its Novel AI-Accelerated Drug Discovery Platform—PhAROS™
As digitization becomes a necessity in the life sciences industry, Gb Sciences proves it's already ahead of the curve with its own revolutionary technology. As digitization becomes a necessity in the ...
TODAY: Gb Sciences' President and Chief Science Officer Presents Keynote Address on Cannabinoid-Containing Formulations for Parkinson's Disease at 2022 NeuroForum Summit
Dr. Andrea Small-Howard explains that Gb Sciences' multicomponent Parkinson's disease therapeutic addresses this multi-factorial neurodegenerative condition using a combination of cannabinoids that ar...
TODAY: Gb Sciences Showcases Its PhAROS™ Drug Discovery Platform at the 2nd ALCOR Drug Discovery Platform Summit
President and Chief Science Officer Dr. Andrea Small-Howard demonstrates the platform's utility for predicting novel plant-inspired drug candidates and describes its role in Gb Sciences' future succes...
TODAY: Gb Sciences' Novel Plant-Inspired Pain Medications Featured at SMi's 22nd Annual Pain Therapeutics Conference
President and Chief Science Officer Dr. Andrea Small-Howard stressed the importance of developing their innovative, plant-inspired formulations as a potentially safer alternative to existing opioid-ba...
Gb Sciences' Nanoparticle Encapsulation Technology Improves the Efficacy of Terpenes for Use in Our Chronic Pain Formulations as Demonstrated in New Research Article
On March 25, the University of Seville, Chaminade University, and Gb Sciences co-published the results from Gb Sciences-sponsored study in the International Journal of Pharmaceutics. Gb Sciences' prop...
UPDATE: Gb Sciences Issues Shareholder Letter
Biopharmaceutical research company specializing in cannabis- and plant-inspired medicines shares strategic plan for 2022 and key developments from 2021 Biopharmaceutical research company specializing ...
Gb Sciences Issues Summary Shareholder Letter
Biopharmaceutical research company specializing in cannabis- and plant-inspired medicines shares strategic plan for 2022 and key developments from 2021 Biopharmaceutical research company specializing ...
Gb Sciences and Michigan State University Researchers Have Identified the Complicated Truth Behind the Opportunity for an Effective Cannabinoid-Based Coronavirus Treatment
Gb Sciences' collaboration with MSU has received media coverage across the country, starting with an interview from WLNS-TV in Lansing, Michigan, and interviews with Gb Sciences in the magazines 'Cann...
Gb Sciences Leaves Cannabis Cultivation With $8M Sale Of Las Vegas Facility, Enters BioPharma Industry
Gb Sciences, Inc. (OTCQB:GBLX) announced Tuesday that it has closed the sale of its last remaining cannabis facility, completing a transition to the biopharmaceutical industry. What Happened Based in ...
Gb Sciences Completes $8 Million Sale of Las Vegas Cannabis Facility
The sale will accelerate the development of Gb Sciences' proprietary Parkinson's disease and COVID-related Cytokine-Release Syndrome therapies The sale will accelerate the development of Gb Sciences' ...
Gb Sciences Starts Preclinical Study for Plant-Based Formulas to Treat Depression and Anxiety
The biopharma technology company's AI-driven PhAROS™ platform has identified novel, plant-inspired formulations that will be tested using preclinical Zebrafish models at the National Research Council ...
Gb Sciences Achieves Positive Proof-of-Concept Results for Their Cytokine Release Syndrome Therapies Designed to Suppress COVID-Related Hyperinflammation
Based on a recently completed preclinical study performed at Michigan State University, Gb Sciences' preclinical data supports further development of their novel cannabinoid-containing complex mixture...
Gb Sciences Presenting COVID-Related Cytokine Release Syndrome Results at H.C. Wainwright's 23rd Annual Global Investment Conference
Highlighting Gb Sciences' Development of Plant-Inspired Therapies for COVID-related Cytokine Release Syndrome, Chronic Pain, and Parkinson's Disease during the Healthcare & Biotech Track starting Mond...
Gb Sciences to Present at the SNN Network Summer Virtual Event on Wednesday, August 18th, 2021
LAS VEGAS, NV / ACCESSWIRE / August 10, 2021 / Gb Sciences (OTCQB:GBLX), a plant-based research and biopharmaceutical drug development company, today announced that it will be presenting at the SNN Ne...
GB Sciences Is Developing Plant-Inspired Mixtures for Anxiety, Depression, and Pain From PhAROS, GB Sciences' Proprietary AI-Accelerated Drug Discovery Platform
GB Sciences used PhAROS™, their novel AI-accelerated drug discovery platform, to identify and pre-validate optimized therapeutic mixtures for the treatment of anxiety, depression, and pain from mixtur...
GB Sciences Using AI Technology in Plant-Based Drug Discovery Research
Biotech innovator GB Sciences has launched a drug discovery platform using AI technology that can identify and predict the efficacy of combinations of novel active ingredients from plants. LAS VEGAS, ...